A brighter future for Monoclonal Antibodies
Our Vision
Current industrial production of monoclonal antibodies (mAbs) via batch chromatography faces significant challenges in terms of high purification costs, and also present environmental concerns due to the extensive use of chemicals. BIOPURE’s innovative new technology allows for mAbs to be recovered directly in the solid-state from clarified cell culture fluids.
Objectives
The BIOPURE team will demonstrate the enhanced productivity and cost reduction of this innovative technology in an industry-relevant environment, through a fully functional prototype that operates in compliance with quality regulations for biopharmaceutical production. The BIOPURE concept will also be validated with actual market players, allowing for a solid go-to-market strategy.
Expected Impact
Biopure expects to lower manufacturing and equipment costs associated with mAbp purification, compared to standard chromatography-based production. In this way, new possibilities in the field of biomedicine can be created that were previously too costly or technologically challenging, while also promoting environmental sustainability.
The end result is aimed at giving patients greater access to more affordable and effective next-generation biomedicines.
Funding
Horizon Europe
Horizon Europe is the ambitious EU research & innovation framework programme for 2021-2027 with a budget of €95.5 billion.
Its overarching goals are:
to strengthen the EU's scientific and technological bases and the European Research Area (ERA);
to boost Europe's innovation capacity, competitiveness and jobs;
to deliver on citizen's priorities and sustain our socio-economic model and values.
With a particular focus on creating impact or the European Green Deal, the digital and sustainability transition and recovery from the coronavirus-crisis.